 |
|
|
| |
The Effect of Fostemsavir on Methadone and The Effect of Fostemsavir on Methadone and Buprenorphine Pharmacokinetics
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science; July 23-26, 2017; Paris, France
Heather Sevinsky,1Mindy Magee,2Peter Ackerman,3Ming Chang,4Susan Lubin,4Elsa Myers,4Wende Wu,5Cyril Llamoso,3Timothy Eley5
1ViiV Healthcare, Upper Providence, PA, USA; 2GlaxoSmithKline, Upper Merion, PA, USA; 3ViiV Healthcare, Wallingford, CT, USA; 4Bristol-Myers Squibb, Hopewell, NJ, USA; 5Bristol-Myers Squibb, Lawrenceville, NJ, USA
HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Safety Analysis - (11/02/16)
HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Subgroup Analysis - (10/30/16)
The Effect of Food on the Pharmacokinetics of the HIV-1 Attachment Inhibitor Temsavir, the Active Moiety of the Prodrug Fostemsavir - (06/26/17)
The Effect of Increased Gastric pH on the Bioavailability of Extended Release Tablet of Fostemsavir in Healthy Subjects / Combinectin-GSK3732394 / 2nd Gen Maturation Inhibitor GSK2838232 - (06/26/17)
Pharm Wk: Early Safety, Tolerability and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects - (06/20/17)
HIV Combinectin GSK3732394: A Long-Acting Inhibitor With Multiple Modes of Action - (10/30/16)
|
| |
|
|
|
|
|
